Recombinetics

Recombinetics specializes in gene editing across four business lines operated under its three subsidiaries: 1) Acceligen—for precision animal breeding; 2) Surrogen—for gene edited swine models of human diseases; 3) Regenevida—for tissue engineering and organ transplantation; and 4) Makana Therapeutics—for xenotransplantation in humans. 

Surrogen uses multiple gene editing technologies including CRISPR and TALEN and uses pig models that have similar anatomy, physiology, and size to human patients, having already established its use in preclinical research. In September 2020, Surrogen demonstrated the first genetically engineered large animal model of Glioblastoma achieved through somatic cell gene editing. 

As of March 2024, the company's pipeline (via its subsidiary Therillume) included 10 candidates for the treatment of Glioblastoma and Neurofibromatosis Types 1 and 2. Seven of its candidates (six for Glioblastoma and one for Neurofibromatosis) were in Phase I of clinical testing while its other three candidates were in preclinical stages.

Key customers and partnerships

In October 2020, Recombinetics, via Surrogen, partnered with American Preclinical Services to study and improve the outcomes of its Glioblastoma animal models. 

Funding and financials 

In August 2018, Recombinetics raised USD 34 million in a Series A funding round (lead investors undisclosed), which brought the total funds raised by the company to USD 67.9 million. The funds were earmarked for accelerating the R&D efforts of the company, growing the team, and expanding laboratory facilities and other capabilities.